From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development

Journal of Autoimmunity

Volumn 54, Issue , 2014, Pages 33-50

  Ben Nun, Avraham ^a   Kaushansky, Nathali ^a   Kawakami, Naoto ^b,d   Krishnamoorthy, Gurumoorthy ^b   Berer, Kerstin ^b   Liblau, Roland ^c   Hohlfeld, Reinhard ^d   Wekerle, Hartmut ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^c INSERM   (France)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antigen based immune specific therapy; Experimental autoimmune encephlalomyelitis (EAE); HLA II transgenic mice; Humanized EAE models; Multiple sclerosis (MS); Spontaneous EAE models

Indexed keywords

GLATIRAMER; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RABIES VACCINE; T LYMPHOCYTE RECEPTOR; MOG PROTEIN, HUMAN; MOG PROTEIN, MOUSE;

ANTIGEN BASED IMMUNE SPECIFIC THERAPY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BRAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DEMYELINATING DISEASE; DEMYELINATION; DISEASE COURSE; DISEASE MODEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; HUMANIZED EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RABIES; REVIEW; SPINAL CORD; SPONTANEOUS EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; VACCINATION; ANIMAL; CHEMICALLY INDUCED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; MOUSE; PATHOLOGY;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN;

EID: 84908365143     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.06.004     Document Type: Review

References (201)

1. Rivers T.M., Sprunt D.H., Berry G.P. Observations on attempts to produce acute Disseminated encephalomyelitis in monkeys. JExp Med 1933, 58(1):39-53.
2. Laatsch R.H., Kies M.W., Gordon S., Alvord E.C. The encephalomyelitic activity of myelin isolated by ultracentrifugation. JExp Med 1962, 115:777-788.
3. Experimental allergic encephalomyelitis, a useful model for multiple sclerosis. Progress in clinical and biological research 1984, 146:1-554.
4. Antel J., Antel S., Caramanos Z., Arnold D.L., Kuhlmann T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?. Acta Neuropathol 2012, 123(5):627-638.
5. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. NEngl J Med 2000, 343(13):938-952.
6. Marrie R.A. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 2004, 3(12):709-718.
7. International Multiple Sclerosis Genetics C, Beecham A.H., Patsopoulos N.A., Xifara D.K., Davis M.F., Kemppinen A., et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013, 45(11):1353-1360.
8. Skulina C., Schmidt S., Dornmair K., Babbe H., Roers A., Rajewsky K., et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A 2004, 101(8):2428-2433.
9. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747.
10. Ben-Nun A., Wekerle H., Cohen I.R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981, 11(3):195-199.
11. Ben-Nun A., Wekerle H., Cohen I.R. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981, 292(5818):60-61.
12. Krishnamoorthy G., Wekerle H. EAE: an immunologist's magic eye. Eur J Immunol 2009, 39(8):2031-2035.
13. de Rosbo N.K., Ben-Nun A. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. JAutoimmun 1998, 11(4):287-299.
14. Levine S., Sowinski R. Experimental allergic encephalomyelitis in inbred and outbred mice. JImmunol 1973, 110(1):139-143.
15. Bernard C.C., Carnegie P.R. Experimental autoimmune encephalomyelitis in mice: immunologic response to mouse spinal cord and myelin basic proteins. JImmunol 1975, 114(5):1537-1540.
16. Pettinelli C.B., Fritz R.B., Chou C.H., McFarlin D.E. Encephalitogenic activity of guinea pig myelin basic protein in the SJL mouse. JImmunol 1982, 129(3):1209-1211.
17. Ben-Nun A., Lando Z. Detection of autoimmune cells proliferating to myelin basic protein and selection of T cell lines that mediate experimental autoimmune encephalomyelitis (EAE) in mice. JImmunol 1983, 130(3):1205-1209.
18. Fritz R.B., Chou C.H., McFarlin D.E. Induction of experimental allergic encephalomyelitis in PL/J and (SJL/J x PL/J)F1 mice by myelin basic protein and its peptides: localization of a second encephalitogenic determinant. JImmunol 1983, 130(1):191-194.
19. Zamvil S.S., Mitchell D.J., Moore A.C., Kitamura K., Steinman L., Rothbard J.B. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986, 324(6094):258-260.
20. Zamvil S., Nelson P., Trotter J., Mitchell D., Knobler R., Fritz R., et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 1985, 317(6035):355-358.
21. Acha-Orbea H., Mitchell D.J., Timmermann L., Wraith D.C., Tausch G.S., Waldor M.K., et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988, 54(2):263-273.
22. Heber-Katz E., Acha-Orbea H. The V-region disease hypothesis: evidence from autoimmune encephalomyelitis. Immunol Today 1989, 10(5):164-169.
23. Ben-Nun A., Kerlero de Rosbo N., Kaushansky N., Eisenstein M., Cohen L., Kaye J.F., et al. Anatomy of T cell autoimmunity to myelin oligodendrocyte glycoprotein (MOG): prime role of MOG44F in selection and control of MOG-reactive T cells in H-2b mice. Eur J Immunol 2006, 36(2):478-493.
24. Gaur A., Boehme S.A., Chalmers D., Crowe P.D., Pahuja A., Ling N., et al. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. JNeuroimmunol 1997, 74(1-2):149-158.
25. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996, 379(6563):343-346.
26. Sloan-Lancaster J., Evavold B.D., Allen P.M. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993, 363(6425):156-159.
27. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000, 6(10):1176-1182.
28. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6(10):1167-1175.
29. Sela M. The concept of specific immune treatment against autoimmune diseases. Int Rev Immunol 1999, 18(3):201-216.
30. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971, 1(4):242-248.
31. Teitelbaum D., Webb C., Bree M., Meshorer A., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 1974, 3(2):256-262.
32. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45(7):1268-1276.
33. Teitelbaum D., Fridkis-Hareli M., Arnon R., Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. JNeuroimmunol 1996, 64(2):209-217.
34. Ben-Nun A., Mendel I., Bakimer R., Fridkis-Hareli M., Teitelbaum D., Arnon R., et al. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. JNeurology 1996, 243(4 Suppl 1):S14-S22.
35. Lalive P.H., Neuhaus O., Benkhoucha M., Burger D., Hohlfeld R., Zamvil S.S., et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011, 25(5):401-414.
36. Hong J., Li N., Zhang X., Zheng B., Zhang J.Z. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A 2005, 102(18):6449-6454.
37. Kala M., Rhodes S.N., Piao W.H., Shi F.D., Campagnolo D.I., Vollmer T.L. Bcells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp neurol 2010, 221(1):136-145.
38. Van Kaer L. Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players. Exp neurol 2011, 227(1):19-23.
39. Ziemssen T., Kumpfel T., Klinkert W.E., Neuhaus O., Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain J Neurol 2002, 125(Pt 11):2381-2391.
40. Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. JNeurosci Off J Soc Neurosci 2005, 25(36):8217-8228.
41. Gillis S., Ferm M.M., Ou W., Smith K.A. Tcell growth factor: parameters of production and a quantitative microassay for activity. JImmunol 1978, 120(6):2027-2032.
42. Naparstek Y., Ben-Nun A., Holoshitz J., Reshef T., Frenkel A., Rosenberg M., et al. Tlymphocyte lines producing or vaccinating against autoimmune encephalomyelitis (EAE). Functional activation induces peanut agglutinin receptors and accumulation in the brain and thymus of line cells. Eur J Immunol 1983, 13(5):418-423.
43. Lider O., Reshef T., Beraud E., Ben-Nun A., Cohen I.R. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 1988, 239(4836):181-183.
44. Schluesener H.J., Wekerle H. Autoaggressive T lymphocyte lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocyte populations. JImmunol 1985, 135(5):3128-3133.
45. Beraud E., Lider O., Baharav E., Reshef T., Cohen I.R. Vaccination against experimental autoimmune encephalomyelitis using a subencephalitogenic dose of autoimmune effector cells (1). Characteristics of vaccination. JAutoimmun 1989, 2(1):75-86.
46. Karussis D., Shor H., Yachnin J., Lanxner N., Amiel M., Baruch K., et al. Tcell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial. PloS one 2012, 7(12):e50478.
47. Flugel A., Willem M., Berkowicz T., Wekerle H. Gene transfer into CD4+ T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat Med 1999, 5(7):843-847.
48. Flugel A., Berkowicz T., Ritter T., Labeur M., Jenne D.E., Li Z., et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001, 14(5):547-560.
49. Odoardi F., Sie C., Streyl K., Ulaganathan V.K., Schlager C., Lodygin D., et al. Tcells become licensed in the lung to enter the central nervous system. Nature 2012, 488(7413):675-679.
50. Kawakami N., Lassmann S., Li Z., Odoardi F., Ritter T., Ziemssen T., et al. The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. JExp Med 2004, 199(2):185-197.
51. Auffray C., Fogg D., Garfa M., Elain G., Join-Lambert O., Kayal S., et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007, 317(5838):666-670.
52. Phillipson M., Heit B., Colarusso P., Liu L., Ballantyne C.M., Kubes P. Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. JExp Med 2006, 203(12):2569-2575.
53. Li W., Nava R.G., Bribriesco A.C., Zinselmeyer B.H., Spahn J.H., Gelman A.E., et al. Intravital 2-photon imaging of leukocyte trafficking in beating heart. JClin Invest 2012, 122(7):2499-2508.
54. Nourshargh S., Hordijk P.L., Sixt M. Breaching multiple barriers: leukocyte motility through venular walls and the interstitium. Nat Rev Mol Cell biol 2010, 11(5):366-378.
55. Kivisakk P., Imitola J., Rasmussen S., Elyaman W., Zhu B., Ransohoff R.M., et al. Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol 2009, 65(4):457-469.
56. Pesic M., Bartholomaus I., Kyratsous N.I., Heissmeyer V., Wekerle H., Kawakami N. 2-photon imaging of phagocyte-mediated T cell activation in the CNS. JClin Invest 2013, 123(3):1192-1201.
57. Lodygin D., Odoardi F., Schlager C., Korner H., Kitz A., Nosov M., et al. Acombination of fluorescent NFAT and H2B sensors uncovers dynamics of T cell activation in real time during CNS autoimmunity. Nat Med 2013, 19(6):784-790.
58. Marangoni F., Murooka T.T., Manzo T., Kim E.Y., Carrizosa E., Elpek N.M., et al. The transcription factor NFAT exhibits signal memory during serial T cell interactions with antigen-presenting cells. Immunity 2013, 38(2):237-249.
59. Mues M., Bartholomaus I., Thestrup T., Griesbeck O., Wekerle H., Kawakami N., et al. Real-time in vivo analysis of T cell activation in the central nervous system using a genetically encoded calcium indicator. Nat Med 2013, 19(6):778-783.
60. Waksman B.H., Porter H., Lees M.D., Adams R.D., Folch J. Astudy of the chemical nature of components of bovine white matter effective in producing allergic encephalomyelitis in the rabbit. JExp Med 1954, 100(5):451-471.
61. Williams R.M., Lees M.B., Cambi F., Macklin W.B. Chronic experimental allergic encephalomyelitis induced in rabbits with bovine white matter proteolipid apoprotein. JNeuropathol Exp Neurol 1982, 41(5):508-521.
62. Sobel R.A., van der Veen R.C., Lees M.B. The immunopathology of chronic experimental allergic encephalomyelitis induced in rabbits with bovine proteolipid protein. JImmunol 1986, 136(1):157-163.
63. Satoh J., Sakai K., Endoh M., Koike F., Kunishita T., Namikawa T., et al. Experimental allergic encephalomyelitis mediated by murine encephalitogenic T cell lines specific for myelin proteolipid apoprotein. JImmunol 1987, 138(1):179-184.
64. Tuohy V.K., Lu Z.J., Sobel R.A., Laursen R.A., Lees M.B. Asynthetic peptide from myelin proteolipid protein induces experimental allergic encephalomyelitis. JImmunol 1988, 141(4):1126-1130.
65. Whitham R.H., Bourdette D.N., Hashim G.A., Herndon R.M., Ilg R.C., Vandenbark A.A., et al. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis. JImmunol 1991, 146(1):101-107.
66. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. JExp Med 1995, 182(1):75-85.
67. Waldner H., Whitters M.J., Sobel R.A., Collins M., Kuchroo V.K. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc Natl Acad Sci U S A 2000, 97(7):3412-3417.
68. Kaye J.F., Kerlero de Rosbo N., Mendel I., Flechter S., Hoffman M., Yust I., et al. The central nervous system-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS). JNeuroimmunol 2000, 102(2):189-198.
69. Zhong M.C., Cohen L., Meshorer A., Kerlero de Rosbo N., Ben-Nun A T-cells specific for soluble recombinant oligodendrocyte-specific protein induce severe clinical experimental autoimmune encephalomyelitis in H-2(b) and H-2(s) mice. JNeuroimmunol 2000, 105(1):39-45.
70. Karnezis T., Mandemakers W., McQualter J.L., Zheng B., Ho P.P., Jordan K.A., et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci 2004, 7(7):736-744.
71. Kela-Madar N., de Rosbo N.K., Ronen A., Mor F., Ben-Nun A. Autoimmune spread to myelin is associated with experimental autoimmune encephalomyelitis induced by a neuronal protein, beta-synuclein. JNeuroimmunol 2009, 208(1-2):19-29.
72. Huizinga R., Gerritsen W., Heijmans N., Amor S. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis 2008, 32(3):461-470.
73. Amor S., Groome N., Linington C., Morris M.M., Dornmair K., Gardinier M.V., et al. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. JImmunol 1994, 153(10):4349-4356.
74. Mendel I., Kerlero de Rosbo N., Ben-Nun A. Amyelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995, 25(7):1951-1959.
75. Stevens D.B., Chen K., Seitz R.S., Sercarz E.E., Bronstein J.M. Oligodendrocyte-specific protein peptides induce experimental autoimmune encephalomyelitis in SJL/J mice. JImmunol 1999, 162(12):7501-7509.
76. Kerlero de Rosbo N., Milo R., Lees M.B., Burger D., Bernard C.C., Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. JClin Invest 1993, 92(6):2602-2608.
77. Holz A., Bielekova B., Martin R., Oldstone M.B. Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis. JImmunol 2000, 164(2):1103-1109.
78. Vu T., Myers L.W., Ellison G.W., Mendoza F., Bronstein J.M. T-cell responses to oligodendrocyte-specific protein in multiple sclerosis. JNeurosci Res 2001, 66(3):506-509.
79. Schluesener H.J., Sobel R.A., Linington C., Weiner H.L. Amonoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. JImmunol 1987, 139(12):4016-4021.
80. Linington C., Bradl M., Lassmann H., Brunner C., Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988, 130(3):443-454.
81. Kerlero de Rosbo N., Honegger P., Lassmann H., Matthieu J.M. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. JNeurochem 1990, 55(2):583-587.
82. Xiao B.G., Linington C., Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. JNeuroimmunol 1991, 31(2):91-96.
83. Sun J., Link H., Olsson T., Xiao B.G., Andersson G., Ekre H.P., et al. Tand B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. JImmunol 1991, 146(5):1490-1495.
84. Kerlero de Rosbo N., Hoffman M., Mendel I., Yust I., Kaye J., Bakimer R., et al. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol 1997, 27(11):3059-3069.
85. Wallstrom E., Khademi M., Andersson M., Weissert R., Linington C., Olsson T. Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. Eur J Immunol 1998, 28(10):3329-3335.
86. Saez-Torres I., Brieva L., Espejo C., Barrau M.A., Montalban X., Martinez-Caceres E.M. Specific proliferation towards myelin antigens in patients with multiple sclerosis during a relapse. Autoimmunity 2002, 35(1):45-50.
87. Linington C., Berger T., Perry L., Weerth S., Hinze-Selch D., Zhang Y., et al. Tcells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 1993, 23(6):1364-1372.
88. Kerlero de Rosbo N., Mendel I., Ben-Nun A. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur J Immunol 1995, 25(4):985-993.
89. Mendel Kerlero de Rosbo N., Ben-Nun A. Delineation of the minimal encephalitogenic epitope within the immunodominant region of myelin oligodendrocyte glycoprotein: diverse V beta gene usage by T cells recognizing the core epitope encephalitogenic for T cell receptor V beta b and T cell receptor V beta a H-2b mice. Eur J Immunol 1996, 26(10):2470-2479.
90. Berard J.L., Wolak K., Fournier S., David S. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 2010, 58(4):434-445.
91. Scheikl T., Pignolet B., Mars L.T., Liblau R.S. Transgenic mouse models of multiple sclerosis. Cell Mol life Sci 2010, 67(23):4011-4034.
92. Rangachari M., Kuchroo V.K. Using EAE to better understand principles of immune function and autoimmune pathology. JAutoimmun 2013, 45:31-39.
93. Traugott U., Reinherz E.L., Raine C.S. Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. JNeuroimmunol 1983, 4(3):201-221.
94. Hauser S.L., Bhan A.K., Gilles F., Kemp M., Kerr C., Weiner H.L. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 1986, 19(6):578-587.
95. Jersild C., Svejgaard A., Fog T. HL-A antigens and multiple sclerosis. Lancet 1972, 1(7762):1240-1241.
96. Kaur G., Trowsdale J., Fugger L. Natural killer cells and their receptors in multiple sclerosis. Brain J Neurol 2013, 136(Pt 9):2657-2676.
97. Rawji K.S., Yong V.W. The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin Dev Immunol 2013, 2013:948976.
98. Anderson A.C., Chandwaskar R., Lee D.H., Sullivan J.M., Solomon A., Rodriguez-Manzanet R., et al. Atransgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ T and B cells. JImmunol 2012, 188(5):2084-2092.
99. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. JExp Med 2000, 192(3):393-404.
100. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain J Neurol 2009, 132(Pt 5):1175-1189.
101. Honma K., Parker K.C., Becker K.G., McFarland H.F., Coligan J.E., Biddison W.E. Identification of an epitope derived from human proteolipid protein that can induce autoreactive CD8+ cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism. JNeuroimmunol 1997, 73(1-2):7-14.
102. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A., et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004, 103(11):4222-4231.
103. Jurewicz A., Biddison W.E., Antel J.P. MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. JImmunol 1998, 160(6):3056-3059.
104. Berthelot L., Laplaud D.A., Pettre S., Ballet C., Michel L., Hillion S., et al. Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals. Eur J Immunol 2008, 38(7):1889-1899.
105. Mars L.T., Saikali P., Liblau R.S., Arbour N. Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. Biochim Biophys Acta 2011, 1812(2):151-161.
106. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172(1):146-155.
107. Huseby E.S., Liggitt D., Brabb T., Schnabel B., Ohlen C., Goverman J. Apathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. JExp Med 2001, 194(5):669-676.
108. Sun D., Whitaker J.N., Huang Z., Liu D., Coleclough C., Wekerle H., et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. JImmunol 2001, 166(12):7579-7587.
109. Friese M.A., Jakobsen K.B., Friis L., Etzensperger R., Craner M.J., McMahon R.M., et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat Med 2008, 14(11):1227-1235.
110. Sasaki K., Bean A., Shah S., Schutten E., Huseby P.G., Peters B., et al. Relapsing-remitting central nervous system autoimmunity mediated by GFAP-specific CD8 T cells. JImmunol 2014, 192(7):3029-3042.
111. Koh D.R., Fung-Leung W.P., Ho A., Gray D., Acha-Orbea H., Mak T.W. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science 1992, 256(5060):1210-1213.
112. Najafian N., Chitnis T., Salama A.D., Zhu B., Benou C., Yuan X., et al. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. JClin Invest 2003, 112(7):1037-1048.
113. Chen M.L., Yan B.S., Kozoriz D., Weiner H.L. Novel CD8+ Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms. Eur J Immunol 2009, 39(12):3423-3435.
114. Lee Y.H., Ishida Y., Rifa'i M., Shi Z., Isobe K., Suzuki H. Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. JImmunol 2008, 180(2):825-832.
115. Zozulya A.L., Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 2008, 4(7):384-398.
116. Correale J., Villa A. Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis. JNeuroimmunol 2008, 195(1-2):121-134.
117. Karandikar N.J., Crawford M.P., Yan X., Ratts R.B., Brenchley J.M., Ambrozak D.R., et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. JClin Invest 2002, 109(5):641-649.
118. Tennakoon D.K., Mehta R.S., Ortega S.B., Bhoj V., Racke M.K., Karandikar N.J. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. JImmunol 2006, 176(11):7119-7129.
119. Feger U., Tolosa E., Huang Y.H., Waschbisch A., Biedermann T., Melms A., et al. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood 2007, 110(2):568-577.
120. Prineas J.W., Wright R.G. Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978, 38:409-421.
121. Kabat E.A., Moore D.H., Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. JClin Invest 1942, 21(5):571-577.
122. Lowenthal A., Vansande M., Karcher D. The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins. JNeurochem 1960, 6(1):51-56.
123. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. NEngl J Med 2003, 349(2):139-145.
124. Cross A.H., Trotter J.L., Lyons J.A. Bcells and antibodies in CNS demyelinating disease. JNeuroimmunol 2001, 112:1-14.
125. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. NEngl J Med 2008, 358(7):676-688.
126. Genain C.P., Nguyen M.H., Letvin N.L., Pearl R., Davis R.L., Adelmann M., et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. JClin Invest 1995, 96:2966-2974.
127. Lyons J.A., Ramsbottom M.J., Cross A.H. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur J Immunol 2002, 32(7):1905-1913.
128. Lyons J.A., San M., Happ M.P., Cross A.H. Bcells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 1999, 29(11):3432-3439.
129. Marta C.B., Oliver A.R., Sweet R.A., Pfeiffer S.E., Ruddle N.H. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 2005, 102:13992-13997.
130. Litzenburger T., Fässler R., Bauer J., Lassmann H., Linington C., Wekerle H., et al. Blymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. JExp Med 1998, 188(1):169-180.
131. Linington C., Webb M., Woodhams P.L. Anovel myelin-associated glycoprotein defined by a mouse monoclonal antibody. JNeuroimmunol 1984, 6(6):387-396.
132. Hjelmström P., Juedes A.E., Fjell J., Ruddle N.H. Bcell deficient mice developexperimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein immunization. JImmunol 1998, 161:4480-4483.
133. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M. Bcells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3(10):944-950.
134. Wolf S.D., Dittel B.N., Hardardottir F., Janeway C.A. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. JExp Med 1996, 184(6):2271-2278.
135. Matsushita T., Fujimoto M., Hasegawa M., Komura K., Takehara K., Tedder T.F., et al. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am J Pathol 2006, 168(3):812-821.
136. Molnarfi N., Schulze Topphoff U., Weber M.S., Patarroyo J.C., Prodhomme T., Varrin-Doyer M., et al. MHC class II dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin specific autoantibodies. JExp Med 2013, 13:2921-2937.
137. Mann M.K., Maresz K., Shriver L.P., Tan Y.P., Dittel B.N. Bcell regulation of CD4+CD25+T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. JImmunol 2007, 178(6):3447-3456.
138. Barr T.A., Shen P., Brown S., Lampropoulou V., Roch T., Lawrie S., et al. Bcell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. JExp Med 2012, 209(5):1001-1010.
139. Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. JImmunol 2007, 178(10):6092-6099.
140. Shen P., Roch T., Lampropoulou V., O'Connor R.A., Stervbo U., Hilgenberg E., et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014, 507:366-370.
141. Krishnamoorthy G., Lassmann H., Wekerle H., Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. JClin Invest 2006, 116(9):2385-2392.
142. Bettelli E., Baeten D., Jäger A., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. JClin Invest 2006, 116(9):2393-2402.
143. Pöllinger B., Krishnamoorthy G., Berer K., Lassmann H., Bösl M., Dunn R., et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. JExp Med 2009, 206(6):1303-1316.
144. Berer K., Wekerle H., Krishnamoorthy G. Bcells in spontaneous autoimmune diseases of the central nervous system. Mol Immunol 2011, 48(11):1332-1337.
145. Berer K., Mues M., Koutroulos M., Al Rasbi Z., Boziki M., Johner C., et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011, 479(7374):538-541.
146. Matsushita T., Yanaba K., Bouaziz J.D., Fujimoto M., Tedder T.F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. JClin Invest 2008, 118(10):3420-3430.
147. Weber M.S., Prod'homme T., Patarroyo J.C., Molnarfi N., Karnezis T., Lehmann-Horn K., et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010, 69(3):360-383.
148. Krishnamoorthy G., Holz A., Wekerle H. Experimental models of spontaneous autoimmune disease in the central nervous system. JMol Med 2007, 85(11):1161-1173.
149. Goverman J., Woods A., Larson L., Weiner L.P., Hood L., Zaller D.M. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993, 72(4):551-560.
150. Lafaille J.J., Nagashima K., Katsuki M., Tonegawa S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994, 78(3):399-408.
151. Olivares-Villagómez D., Wang Y., Lafaille J.J. Regulatory CD4+T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. JExp Med 1998, 188(10):1883-1894.
152. Anderson A.C., Nicholson L.B., Legge K.L., Turchin V., Zaghouani H., Kuchroo V.K. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. JExp Med 2000, 191:761-770.
153. Waldner H., Collins M., Kuchroo V.K. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. JClin Invest 2004, 113(7):990-997.
154. Bettelli E., Pagany M., Weiner H.L., Linington C., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. JExp Med 2003, 197(9):1073-1081.
155. Berer K., Boziki M., Krishnamoorthy G. Selective accumulation of pro-inflammatory t cells in the intestine contributes to the resistance to autoimmune demyelinating disease. PLoS ONE 2014, 9(2):e87876.
156. Perchellet A., Stromnes I., Pang J.M., Goverman J. CD8+T cells maintain tolerance to myelin basic protein by 'epitope theft'. Nat Immunol 2004, 5(6):606-614.
157. Ji Q.Y., Perchellet A., Goverman J.M. Viral infection triggers central nervous system autoimmunity via activation of CD8+T cells expressing dual TCRs. Nat Immunol 2010, 11(7):628-634.
158. Na S.Y., Cao Y., Toben T., Nitschke L., Stadelmann C., Gold R., et al. Naïve CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain 2008, 131(9):2353-2365.
159. Saxena A., Bauer J., Scheikl T., Zappulla J., Audebert M., Desbois S., et al. Multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. JImmunol 2008, 181(3):1617-1621.
160. Madsen L.S., Andersson E.C., Jansson L., Krogsgaard M., Andersen C.B., Engsberg J., et al. Ahumanized model for multiple sclerosis using HLA DR2 and a human T cell receptor. Nat Genet 1999, 23:343-347.
161. Gregersen J.W., Kranc K.R., Ke X., Svendsen P., Madsen L.S., Thomsen A.R., et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 2006, 443(7111):574-577.
162. Ellmerich S., Mycko M., Takács K., Waldner H., Wahid F.N., Boyton R.J., et al. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. JImmunol 2005, 174(4):1938-1946.
163. Compston D.A., Batchelor J.R., McDonald W.I. B-lymphocyte allossantigens associated with multiple sclerosis. Lancet 1976, 2(7998):1261-1265.
164. Olerup O., Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991, 38(1):1-15.
165. Fogdell-Hahn A., Ligers A., Gronning M., Hillert J., Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue antigens 2000, 55(2):140-148.
166. Brynedal B., Duvefelt K., Jonasdottir G., Roos I.M., Akesson E., Palmgren J., et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PloS one 2007, 2(7):e664.
167. Miretti M.M., Walsh E.C., Ke X., Delgado M., Griffiths M., Hunt S., et al. Ahigh-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 2005, 76(4):634-646.
168. Mangalam A., Luckey D., Basal E., Behrens M., Rodriguez M., David C. HLA-DQ6 (DQB1*0601)-restricted T cells protect against experimental autoimmune encephalomyelitis in HLA-DR3.DQ6 double-transgenic mice by generating anti-inflammatory IFN-gamma. JImmunol 2008, 180(11):7747-7756.
169. Wucherpfennig K.W., Zhang J., Witek C., Matsui M., Modabber Y., Ota K., et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. JImmunol 1994, 152(11):5581-5592.
170. Valli A., Sette A., Kappos L., Oseroff C., Sidney J., Miescher G., et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. JClin Invest 1993, 91(2):616-628.
171. Altmann D.M., Douek D.C., Frater A.J., Hetherington C.M., Inoko H., Elliott J.I. The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4. JExp Med 1995, 181(3):867-875.
172. Rich C., Link J.M., Zamora A., Jacobsen H., Meza-Romero R., Offner H., et al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol 2004, 34(5):1251-1261.
173. Kaushansky N., Altmann D.M., Ascough S., David C.S., Lassmann H., Ben-Nun A. HLA-DQB1*0602 determines disease susceptibility in a new "humanized" multiple sclerosis model in HLA-DR15 (DRB1*1501;DQB1*0602) transgenic mice. JImmunol 2009, 183(5):3531-3541.
174. Kaushansky N., Altmann D.M., David C.S., Lassmann H., Ben-Nun A. DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP). JNeuroinflamm 2012, 9:29.
175. Trotter J.L., Pelfrey C.M., Trotter A.L., Selvidge J.A., Gushleff K.C., Mohanakumar T., et al. Tcell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. JNeuroimmunol 1998, 84(2):172-178.
176. Ohashi T., Yamamura T., Inobe J., Kondo T., Kunishita T., Tabira T. Analysis of proteolipid protein (PLP)-specific T cells in multiple sclerosis: identification of PLP 95-116 as an HLA-DR2,w15-associated determinant. Int Immunol 1995, 7(11):1771-1778.
177. Quandt J.A., Huh J., Baig M., Yao K., Ito N., Bryant M., et al. Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. JImmunol 2012, 189(6):2897-2908.
178. Haghikia A., Hohlfeld R., Gold R., Fugger L. Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol Med 2013, 19(5):309-319.
179. Cross A.H., Naismith R.T. Established and novel disease-modifying treatments in multiple sclerosis. JIntern Med 2014, 275(4):350-363.
180. Gonsette R.E., Delmotte P., Demonty L. Failure of basic protein therapy for multiple sclerosis. JNeurol 1977, 216(1):27-31.
181. Campbell B., Vogel P.J., Fisher E., Lorenz R. Myelin basic protein administration in multiple sclerosis. Arch Neurol 1973, 29(1):10-15.
182. Warren K.G., Catz I., Ferenczi L.Z., Krantz M.J. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol Off J Eur Fed Neurol Soc 2006, 13(8):887-895.
183. Steinman L. Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet. Neurother : J Am Soc Exp Neurother 2007, 4(4):661-665.
184. Vandenbark A.A., Hashim G., Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989, 341(6242):541-544.
185. Huan J., Subramanian S., Jones R., Rich C., Link J., Mooney J., et al. Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. JImmunol 2004, 172(7):4556-4566.
186. Offner H., Sinha S., Wang C., Burrows G.G., Vandenbark A.A. Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis. Rev Neurosci 2008, 19(4-5):327-339.
187. Wraith D.C., Smilek D.E., Mitchell D.J., Steinman L., McDevitt H.O. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell 1989, 59(2):247-255.
188. Leadbetter E.A., Bourque C.R., Devaux B., Olson C.D., Sunshine G.H., Hirani S., et al. Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide. JImmunol 1998, 161(1):504-512.
189. Freedman M.S., Bar-Or A., Oger J., Traboulsee A., Patry D., Young C., et al. Aphase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011, 77(16):1551-1560.
190. Lehmann P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992, 358(6382):155-157.
191. Tuohy V.K., Yu M., Yin L., Kawczak J.A., Johnson J.M., Mathisen P.M., et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1998, 164:93-100.
192. Tuohy V.K., Yu M., Weinstock-Guttman B., Kinkel R.P. Diversity and plasticity of self recognition during the development of multiple sclerosis. JClin Invest 1997, 99(7):1682-1690.
193. Yu M., Kinkel R.P., Weinstock-Guttman B., Cook D.J., Tuohy V.K. HLA-DP: a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis. Hum Immunol 1998, 59(1):15-24.
194. Zhong M.C., Kerlero de Rosbo N., Ben-Nun A. Multiantigen/multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene. JClin Invest 2002, 110(1):81-90.
195. Kaushansky N., Kerlero de Rosbo N., Zilkha-Falb R., Yosef-Hemo R., Cohen L., Ben-Nun A. 'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides. PloS one 2011, 6(11):e27860.
196. Musio S., Pedotti P., Mantegazza R., Ohtsu H., Boon L., Steinman L., et al. Anaphylaxis to a self-peptide in the absence of mast cells or histamine. Lab Invest J Tech Meth Pathol 2009, 89(4):398-405.
197. Smith C.E., Miller S.D. Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities. JAutoimmun 2006, 27(4):218-231.
198. Lutterotti A., Yousef S., Sputtek A., Sturner K.H., Stellmann J.P., Breiden P., et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med 2013, 5(188):188ra175.
199. Pillai S. Rethinking mechanisms of autoimmune pathogenesis. JAutoimmun 2013, 45:97-103.
200. Jamin C., Renaudineau Y., Pers J.O. Pierre Youinou: when intuition and determination meet autoimmunity. JAutoimmun 2012, 39(s3):117-120.
201. Eric Gershwin M., Shoenfeld Y., Abbas Abul an epitome of scholarship. JAutoimmun 2013, 45:1-6.